Recent Updates — SHPH
The Audit Committee and Board of Directors dismissed independent registered public accounting firm Forvis Mazars, LLP, effective after the filing of the quarterly report for the period ended September 30, 2026. The dismissal follows previously disclosed material weaknesses in internal control over financial reporting, including ineffective oversight of accounting transaction processing, lack of segregation of duties, deficiencies in IT general controls, and insufficient technical accounting expertise. Forvis Mazars's reports did not contain adverse opinions but included explanatory paragraphs regarding substantial doubt about the company’s ability to continue as a going concern. The company has not yet engaged a successor auditor. Shuttle Pharmaceuticals Holdings, Inc. operates in the pharmaceutical industry.
Shuttle Pharmaceuticals Holdings, Inc. issued 3,737,482 shares of common stock upon the conversion of Series B-1 and Series B-2 Preferred Stock as of September 14, 2026, subject to beneficial ownership limitations. Concurrently, the company issued warrants for approximately 927,114 shares at an exercise price of $10.30 per share and pre-funded warrants for approximately 16,932,508 shares following stockholder approval on September 9, 2026. These unregistered securities were issued in reliance on Section 4(a)(2) exemptions. Shuttle Pharmaceuticals Holdings, Inc. operates in the biopharmaceutical industry, focusing on drug discovery and development.
Shuttle Pharmaceuticals Holdings, Inc. entered into a First Amendment to its Merger Agreement with United Dogecoin Inc., reducing the 'Milestone Event' threshold for Mining Rigs from 2,000 to 500. The company is seeking parallel amendments to its Securities Purchase Agreement and Asset Purchase Agreement to align these definitions. This adjustment modifies the conditions for issuing pre-funded warrants or shares but does not change the maximum number of securities issuable upon satisfying the milestone. Shuttle Pharmaceuticals Holdings, Inc. operates in the pharmaceutical industry.